EUVIMEDEUVIMED entdecken
Open Access

Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials

Avital M Miller iD, Adina H Passy iD, Alexander D Sherry iD, Ramez Kouzy iD, Joseph Abi Jaoude, Timothy A Lin iD, Gabrielle S Kupferman iD, Esther J Beck iD, Pavlos Msaouel iD, Ethan B Ludmir iD

JCO Oncology Practice · 2025

DOI: 10.1200/op-24-00735 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2025. Verfasst von Avital M Miller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Clinical Trials, Phase III as Topic, Neoplasms, Drug-Related Side Effects and Adverse Reactions, Antineoplastic Agents. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE This study aimed to determine complete toxicity reporting (CTR), and the use of subjective toxicity-minimizing language (TML) among phase III oncology trials. METHODS Two-arm superiority-design phase III oncology trials published from 2002 to 2020 were reviewed for toxicity data. CTR was defined as reporting total adverse events (TAEs), total serious adverse events (SAEs), total deaths, and study therapy discontinuations because of toxicity. Guideline concordance was defined according to guidelines published in the BMJ (defined as reporting total SAEs, total deaths, and study therapy discontinuations because of toxicity). TML was defined as a set of terms that subjectively downplay the harm of therapies. RESULTS A total of 407 trials enrolling 322,645 patients were included. Most (51%, n = 207) reported SAEs, 88% (n = 358) reported total deaths, and 84% (n = 340) reported study therapy discontinuation because of toxicity. Although 55% of trials (n = 223) reported TAEs, only 32% (n = 131; 95% credible interval, 28 to 37) fit the criteria for CTR. CTR was more common in trials with industry sponsorship (37%) than with cooperative group sponsorship (4%). All 131 trials where CTR was observed were industry-sponsored, and only 3% (4/131) were cooperative group–sponsored trials. TML was used in 46% of trials (n = 186; 95% credible interval, 41 to 51), with no trial-related factors (including sponsorship source) associated with the odds of TML use. CONCLUSION Toxicity in phase III oncology clinical trials is often incompletely reported and is frequently minimized in its interpretation. Industry-sponsored trials more comprehensively report toxicity than do cooperative group–sponsored trials. CTR may improve patients' and oncologists' understanding of new treatments; thus, a more standardized approach to reporting toxicity data is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase III as TopicNeoplasmsDrug-Related Side Effects and Adverse ReactionsAntineoplastic AgentsAdverse Drug Reaction Reporting SystemsMedical OncologyHumansLanguage

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Radiation Oncology, Stanford University, Stanford, CA.
  • Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Gastrointestinal Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Avital M Miller, Adina H Passy, Alexander D Sherry, Ramez Kouzy, Timothy A Lin, Gabrielle S Kupferman, Esther J Beck, Pavlos Msaouel, Ethan B Ludmir

Förderung

  • NCI NIH HHS

Zitieren

APA

Miller, A. M., Passy, A. H., Sherry, A. D., Kouzy, R., Abi Jaoude, J., Lin, T. A., Kupferman, G. S., Beck, E. J., Msaouel, P., & Ludmir, E. B. (2025). Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials. JCO Oncology Practice. https://doi.org/10.1200/op-24-00735

Vancouver

Miller AM, Passy AH, Sherry AD, Kouzy R, Abi Jaoude J, Lin TA, et al. Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials. JCO Oncology Practice. 2025. doi:10.1200/op-24-00735

BibTeX
@article{Miller2025,
  author = {Miller, Avital M and Passy, Adina H and Sherry, Alexander D and Kouzy, Ramez and Abi Jaoude, Joseph and Lin, Timothy A and Kupferman, Gabrielle S and Beck, Esther J and Msaouel, Pavlos and Ludmir, Ethan B},
  title = {Incomplete Toxicity Reporting and Use of Toxicity-Minimizing Language in Phase III Oncology Trials},
  journal = {JCO Oncology Practice},
  year = {2025},
  doi = {10.1200/op-24-00735}
}
Kostenlos starten →